论文部分内容阅读
目的观察西地那非在治疗慢性非细菌性前列腺炎(CNP)合并勃起功能障碍(ED)时的作用。方法CNP合并ED患者52例,随机分为西地那非组(A组)和对照组(B组)。A组34例,NIH-CPSI评分27.4±9.5,IIEF-5评分10.7±2.8,用α1-受体阻断剂及消炎痛栓治疗4周后加用西地那非治疗6周。B组18例,NIH-CPSI评分27.3±9.6,IIEF-5评分10.9±2.7,持续使用α1-受体阻断剂及消炎痛栓治疗10周。治疗4、10周末行NIH-CPSI和IIEF-5评分并观察疗效。结果4周末,A、B组NIH-CPSI评分分别为13.2±4.7、12.5±4.5,较治疗前均显著下降(P<0.01),2组间比较差异无统计学意义(P>0.05);A、B组IIEF-5评分分别为14.1±4.3、14.8±4.6,较治疗前均显著上升(P<0.01),2组间比较差异无统计学意义(P>0.05)。NIH-CPSI评分改变值与自身IIEF-5评分改变值无明显相关性。10周末,A组NIH-CPSI评分9.4±3.6,IIEF-5评分19.1±4.0,与4周末比较差异均有统计学意义(P<0.01);B组NIH-CPSI评分12.9±5.1,IIEF-5评分14.8±5.0,与4周末比较差异均无统计学意义(P>0.05);2组间NIH-CPSI与IIEF-5评分比较差异均有统计学意义(P<0.01)。A组IIEF-5评分改变值与NIH-CPSI评分改变值呈负相关(r=-0.95,P=0.00)。结论对CNP合并ED患者,西地那非在有效治疗ED的同时,还能降低NIH-CPSI评分,促使CNP恢复。
Objective To observe the effect of sildenafil on the treatment of chronic nonbacterial prostatitis (CNP) with erectile dysfunction (ED). Methods 52 patients with CNP combined with ED were randomly divided into sildenafil group (A group) and control group (B group). A group of 34 patients, NIH-CPSI score 27.4 ± 9.5, IIEF-5 score 10.7 ± 2.8, with α1-blockers and indomethacin suppositories for 4 weeks plus sildenafil treatment for 6 weeks. B group, 18 cases, NIH-CPSI score 27.3 ± 9.6, IIEF-5 score 10.9 ± 2.7, continuous use of α1-blockers and indomethacin suppositories for 10 weeks. NIH-CPSI and IIEF-5 scores were measured at 4 and 10 weeks after treatment, and the curative effect was observed. Results At the end of the 4th week, the NIH-CPSI scores in group A and group B were 13.2 ± 4.7 and 12.5 ± 4.5, respectively, which were significantly lower than those before treatment (P <0.01). There was no significant difference between the two groups (P> 0.05). , And the IIEF-5 scores in group B were 14.1 ± 4.3 and 14.8 ± 4.6, respectively, which were significantly higher than those before treatment (P <0.01). There was no significant difference between the two groups (P> 0.05). NIH-CPSI score changes and its own IIEF-5 score change no significant correlation. At 10 weeks, the NIH-CPSI score of group A was 9.4 ± 3.6, the score of IIEF-5 was 19.1 ± 4.0, the difference was statistically significant compared with that at the end of the 4th week (P <0.01); NIH-CPSI score 12.9 ± 5.1, IIEF-5 There was no significant difference between the two groups (P> 0.05). There was significant difference between NIH-CPSI and IIEF-5 scores in both groups (P <0.01). The change of IIEF-5 score in group A was negatively correlated with the change of NIH-CPSI score (r = -0.95, P = 0.00). Conclusion In patients with CNP complicated with ED, sildenafil can effectively reduce the NIH-CPSI score while promoting the recovery of CNP.